Check Jerome H, Dix Ebony, Sansoucie Lynn, Check Diane
Department of Obstetrics and Gynecology, Division of Reproductive Endocrinology and Infertility, The University of Medicine and Dentistry of New Jersey, NJ, U.S.A.
Anticancer Res. 2009 May;29(5):1611-3.
Mifepristone, a progesterone receptor antagonist has been found to improve the length and quality of life in various spontaneous murine cancer models including tumors without progesterone receptors theoretically by inhibiting an immunomodulatory protein that suppresses natural killer cell function in the tumor microenvironment.
Mifepristone 200 mg per day by mouth was given to two patients with stage 4 colon cancer with extensive metastases.
Both patients not only survived far longer than expected but had marked improvement in their quality of life similar to mice. Though the metastatic lesions did not disappear, no new ones appeared for a long time and the ones present did not grow. The drug was extremely well tolerated.
The use of progesterone receptor antagonists may present a novel immunotherapy to help fight cancer. A larger controlled study is needed.
米非司酮是一种孕酮受体拮抗剂，已发现在各种自发性小鼠癌症模型中，包括理论上没有孕酮受体的肿瘤，通过抑制一种免疫调节蛋白来改善生存期和生活质量，该蛋白在肿瘤微环境中抑制自然杀伤细胞功能。
对两名患有广泛转移的4期结肠癌患者口服米非司酮，每日200毫克。
两名患者不仅存活时间远超预期，而且生活质量有显著改善，类似于小鼠。虽然转移病灶没有消失，但很长一段时间内没有出现新的病灶，现有的病灶也没有生长。该药物耐受性极佳。
使用孕酮受体拮抗剂可能是一种新型免疫疗法，有助于对抗癌症。需要进行更大规模的对照研究。
